GE HealthCare Reports Strong Q4 Earnings and Positive 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy GEHC?
Source: Newsfilter
GE HealthCare Technologies Inc. saw its stock rise by 5.53% as it reached a 5-day high following the release of its Q4 2025 earnings report.
The company reported revenues of $5.7 billion for Q4 2025, exceeding expectations by $100 million, and achieved an adjusted EPS of $1.44, beating estimates by $0.04. This strong performance was driven by robust demand in the U.S. and EMEA regions, showcasing the company's operational resilience and effective cost management. Additionally, GE HealthCare provided an optimistic outlook for 2026, projecting organic revenue growth of 3% to 4% and adjusted EPS guidance between $4.95 and $5.15, further boosting investor confidence.
The positive earnings report and favorable guidance have strengthened market sentiment towards GE HealthCare, indicating a solid foundation for future growth amid ongoing market challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 82.310
Low
80.00
Averages
92.25
High
105.00
Current: 82.310
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Texas Instruments Acquires Silicon Labs in $7.5B Deal
- Acquisition Agreement: Texas Instruments is set to acquire Silicon Labs for $231 per share in an all-cash transaction valued at $7.5 billion, which not only boosts Silicon Labs' market valuation but also enhances Texas Instruments' competitive edge in the semiconductor sector.
- Positive Market Reaction: Following the acquisition announcement, Silicon Labs' stock surged by 49%, indicating strong investor confidence in the deal and reflecting optimistic expectations for consolidation within the semiconductor industry.
- Strong Earnings Performance: Silicon Labs reported an adjusted EPS of 56 cents for Q4, slightly above the consensus estimate of 55 cents, demonstrating stable financial performance that enhances the attractiveness of the acquisition.
- Industry Consolidation Trend: This acquisition represents a strategic move for Texas Instruments to expand its product line and signifies an acceleration in semiconductor industry consolidation, potentially triggering more similar deals that could reshape the market landscape.
See More
GE HealthCare Technologies Q4 2025 Earnings Highlights
- Strong Financial Performance: GE HealthCare reported Q4 2025 revenue of $5.7 billion, reflecting a 4.8% year-over-year organic growth that exceeded expectations, showcasing robust demand in pharmaceutical diagnostics and enhancing market competitiveness.
- Acquisition Plans and Growth Outlook: The planned acquisition of Intelerad is projected to add $270 million in annual revenue, accelerating the company's cloud-first imaging ecosystem and enhancing its recurring revenue stream, which is strategically significant for long-term growth.
- Product Launches and Innovation: The commercial availability of Omni total body PET and next-generation SPECT in Europe is expected to drive future order growth, with management reporting a strong three-year vitality rate of 55% for new products, up 5% from the previous year, indicating strong market demand.
- Future Outlook and Risk Management: Management anticipates organic revenue growth of 3% to 4% for 2026, maintaining a cautious outlook for the Chinese market; however, a robust pipeline of new product innovations is expected to support future growth despite challenges.
See More
GE HealthCare Reports Strong Earnings, Stock Surges
- Strong Earnings Report: GE HealthCare reported adjusted earnings of $1.44 per share, surpassing the consensus estimate of $1.40, which reflects the company's robust performance in the healthcare solutions sector and boosts investor confidence.
- Sales Growth: The company achieved sales of $5.69 billion, exceeding expectations of $5.61 billion, with an overall growth of 7.1%, driven by Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions, indicating strong market demand in the U.S. and EMEA regions.
- Order Metrics: Total orders increased organically by 2%, with a book-to-bill ratio of 1.06, demonstrating the company's competitive position and future growth potential, as CEO Arduini highlighted healthy capital investment trends and demand for new products.
- Future Outlook: GE HealthCare forecasts adjusted earnings for 2026 to be between $4.95 and $5.15 per share, exceeding the consensus of $4.92, showcasing the company's confidence in delivering profitable growth and strong cash flow amid a dynamic macro environment.
See More
GE HealthCare Surpasses Expectations with 2026 Outlook
- Earnings Beat: GE HealthCare reported $5.7 billion in Q4 2025 revenue, achieving approximately 7% year-over-year growth that exceeded consensus estimates by $100 million, showcasing strong performance in the U.S. and EMEA markets, which bolsters investor confidence.
- Segment Performance: The Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions segments contributed $790 million, $2.6 billion, and $1.5 billion in revenue, with year-over-year growth rates of approximately 22%, 7%, and 6%, respectively, indicating robust growth potential across multiple business areas.
- Profitability Shift: Although the adjusted EBIT margin slipped 200 basis points to 16.7% compared to the prior year, the adjusted EPS of $1.44 beat expectations by $0.04, demonstrating the company's ability to maintain profitability amid tariff-related challenges.
- 2026 Outlook: GE HealthCare projects an adjusted EPS of $4.59 and revenue of $20.6 billion for 2026, reflecting approximately 5% and 2% year-over-year growth, respectively, with an expected adjusted EPS range of $4.95 to $5.15, indicating a cautiously optimistic outlook for the future.
See More
GE HealthCare Technologies Q4 Earnings Exceed Expectations
- Earnings Beat: GE HealthCare Technologies reported a Q4 Non-GAAP EPS of $1.44, exceeding expectations by $0.04, indicating robust performance in the medical equipment sector and boosting market confidence in future growth.
- Revenue Growth: The company achieved revenue of $5.7 billion, a 7.1% year-over-year increase that surpassed market expectations by $100 million, primarily driven by strong demand in the U.S. and Europe, the Middle East, and Africa, further solidifying its market position.
- Cash Flow Performance: Operating cash flow reached $1.0 billion with free cash flow at $916 million, demonstrating strong financial management and profitability, which supports future investments and shareholder returns.
- 2026 Guidance: The company projects organic revenue growth of 3.0% to 4.0% for 2026, with adjusted EPS expected to be between $4.95 and $5.15, reflecting an optimistic outlook for future performance despite market challenges.
See More
GE HealthCare Shares Climb Following Positive Earnings Report.
- Stock Performance: GE HealthCare Technologies’ stock experienced an increase early Wednesday following the release of its quarterly results.
- Financial Outlook: The company provided a positive outlook for the upcoming year, contributing to investor confidence.
See More
Texas Instruments Acquires Silicon Labs in $7.5B Deal
- Acquisition Agreement: Texas Instruments is set to acquire Silicon Labs for $231 per share in an all-cash transaction valued at $7.5 billion, which not only boosts Silicon Labs' market valuation but also enhances Texas Instruments' competitive edge in the semiconductor sector.
- Positive Market Reaction: Following the acquisition announcement, Silicon Labs' stock surged by 49%, indicating strong investor confidence in the deal and reflecting optimistic expectations for consolidation within the semiconductor industry.
- Strong Earnings Performance: Silicon Labs reported an adjusted EPS of 56 cents for Q4, slightly above the consensus estimate of 55 cents, demonstrating stable financial performance that enhances the attractiveness of the acquisition.
- Industry Consolidation Trend: This acquisition represents a strategic move for Texas Instruments to expand its product line and signifies an acceleration in semiconductor industry consolidation, potentially triggering more similar deals that could reshape the market landscape.
See More
GE HealthCare Technologies Q4 2025 Earnings Highlights
- Strong Financial Performance: GE HealthCare reported Q4 2025 revenue of $5.7 billion, reflecting a 4.8% year-over-year organic growth that exceeded expectations, showcasing robust demand in pharmaceutical diagnostics and enhancing market competitiveness.
- Acquisition Plans and Growth Outlook: The planned acquisition of Intelerad is projected to add $270 million in annual revenue, accelerating the company's cloud-first imaging ecosystem and enhancing its recurring revenue stream, which is strategically significant for long-term growth.
- Product Launches and Innovation: The commercial availability of Omni total body PET and next-generation SPECT in Europe is expected to drive future order growth, with management reporting a strong three-year vitality rate of 55% for new products, up 5% from the previous year, indicating strong market demand.
- Future Outlook and Risk Management: Management anticipates organic revenue growth of 3% to 4% for 2026, maintaining a cautious outlook for the Chinese market; however, a robust pipeline of new product innovations is expected to support future growth despite challenges.
See More
GE HealthCare Reports Strong Earnings, Stock Surges
- Strong Earnings Report: GE HealthCare reported adjusted earnings of $1.44 per share, surpassing the consensus estimate of $1.40, which reflects the company's robust performance in the healthcare solutions sector and boosts investor confidence.
- Sales Growth: The company achieved sales of $5.69 billion, exceeding expectations of $5.61 billion, with an overall growth of 7.1%, driven by Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions, indicating strong market demand in the U.S. and EMEA regions.
- Order Metrics: Total orders increased organically by 2%, with a book-to-bill ratio of 1.06, demonstrating the company's competitive position and future growth potential, as CEO Arduini highlighted healthy capital investment trends and demand for new products.
- Future Outlook: GE HealthCare forecasts adjusted earnings for 2026 to be between $4.95 and $5.15 per share, exceeding the consensus of $4.92, showcasing the company's confidence in delivering profitable growth and strong cash flow amid a dynamic macro environment.
See More
GE HealthCare Surpasses Expectations with 2026 Outlook
- Earnings Beat: GE HealthCare reported $5.7 billion in Q4 2025 revenue, achieving approximately 7% year-over-year growth that exceeded consensus estimates by $100 million, showcasing strong performance in the U.S. and EMEA markets, which bolsters investor confidence.
- Segment Performance: The Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions segments contributed $790 million, $2.6 billion, and $1.5 billion in revenue, with year-over-year growth rates of approximately 22%, 7%, and 6%, respectively, indicating robust growth potential across multiple business areas.
- Profitability Shift: Although the adjusted EBIT margin slipped 200 basis points to 16.7% compared to the prior year, the adjusted EPS of $1.44 beat expectations by $0.04, demonstrating the company's ability to maintain profitability amid tariff-related challenges.
- 2026 Outlook: GE HealthCare projects an adjusted EPS of $4.59 and revenue of $20.6 billion for 2026, reflecting approximately 5% and 2% year-over-year growth, respectively, with an expected adjusted EPS range of $4.95 to $5.15, indicating a cautiously optimistic outlook for the future.
See More
GE HealthCare Technologies Q4 Earnings Exceed Expectations
- Earnings Beat: GE HealthCare Technologies reported a Q4 Non-GAAP EPS of $1.44, exceeding expectations by $0.04, indicating robust performance in the medical equipment sector and boosting market confidence in future growth.
- Revenue Growth: The company achieved revenue of $5.7 billion, a 7.1% year-over-year increase that surpassed market expectations by $100 million, primarily driven by strong demand in the U.S. and Europe, the Middle East, and Africa, further solidifying its market position.
- Cash Flow Performance: Operating cash flow reached $1.0 billion with free cash flow at $916 million, demonstrating strong financial management and profitability, which supports future investments and shareholder returns.
- 2026 Guidance: The company projects organic revenue growth of 3.0% to 4.0% for 2026, with adjusted EPS expected to be between $4.95 and $5.15, reflecting an optimistic outlook for future performance despite market challenges.
See More
GE HealthCare Shares Climb Following Positive Earnings Report.
- Stock Performance: GE HealthCare Technologies’ stock experienced an increase early Wednesday following the release of its quarterly results.
- Financial Outlook: The company provided a positive outlook for the upcoming year, contributing to investor confidence.
See More
